WST · West Pharmaceutical Services Q2 FY2026 earnings call record财报电话会记录

“We now anticipate organic revenue growth to be 10%-11% for the full year and adjusted EPS to be in the range of $8.85-$9.05.”

“This is important for West, as these customers tend to use the highest quality components.”

“We saw continued growth in Annex 1 related projects in the quarter, and we expect this mix shift to deliver on our target of 200 basis points of revenue growth in 2026.”

“Looking ahead, West continues to benefit from generic GLP-1 launches as customers often use the same high-value components, specifically stoppers, plungers, and line seals for primary containment as the most efficient path to commercialization.”

“As Eric mentioned, we had a strong second quarter as revenues of $872 million increased 13.8% on a reported basis and grew 12.7% organically, exceeding our expectations overall.”

“This strong performance was driven by our proprietary segment, which increased 15.5% on an organic basis, while the West Vantage segment grew 0.8%.”

“Total company gross margin was 37.7% in the quarter, up 200 basis points year-over-year.”

“Capital Expenditures were $43 million, down from $75 million in the prior year as we continue to improve capital spending efficiency, focusing on growth and increased financial returns.”

“In Q2, we repurchased just over 0.5 million shares for $157 million and paid out $16 million in dividends.”

“In the first half of the year, we repurchased 1.8 million shares for $454 million and paid out $32 million in dividends.”

“Of the $55 million SmartDose sales in the second half of last year, we generated $30 million in Q3 and have adjusted our third quarter organic sales guidance for those revenues.”

“I don't know if you've had any conversations with your customers on how they think that will ramp and what the ordering patterns will be there and what's kind of contemplated in the guide from a GLP-1 perspective.”